Figure 4. Synergistic effects of the combination of trabectedin and olaparib on DNA damage as detected by COMET assay in four different breast cancer cell lines. Representative images and quantification of damaged DNA in the comet assay in untreated and drug-treated MCF7 (A), MDA-MB-236 (B), MDA-MB-436 (C), and HCC-1937 (D) breast cancer cells. All cell lines were analyzed through comet assay followed by exposure to olaparib, trabectedin, and the combination of trabectedin/olaparib as described in Methods section.
NT=non-treated; Olap =olaparib; Trab=trabectedin; Combo=combination.